Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9413251 | 0.82 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7775837 | 0.76 | LMNA (0.51) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL8780052 | 0.75 | LMNA (0.47) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL9852541 | 0.74 | LMNA (0.61) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL8600920 | 0.74 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL8600919 | 0.74 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5682572 | 0.73 | LMNA (0.56) | LMNASMN1; SMN2 | |
| SCHEMBL333577 | 0.73 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL23559448 | 0.73 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3244970 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090081297-A1 | Use of surface tension reducing agents in aerosol formulations | MAP PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | claimed |
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | BAXTER HEALTHCARE SA (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11052043-B2 | Sustained-release injectable formulation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-07-06 | — | — | US | disclosed |
| US-10952965-B2 | Compositions and methods for drug delivery | BAXTER INTERNATIONAL INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10722463-B2 | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier | ZULI HOLDINGS LTD. (IL) | 2020-07-28 | — | — | US | disclosed |
| US-20180193265-A1 | COMPOSITIONS AND METHODS USING SAME FOR DELIVERING AGENTS INTO A TARGET ORGAN PROTECTED BY A BLOOD BARRIER | ZULI HOLDINGS LTD. (IL) | 2018-07-12 | — | — | US | disclosed |
| US-9943481-B2 | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier | BIOREST LTD. (IL) | 2018-04-17 | — | — | US | disclosed |
| EP-2317982-B1 | METHODS OF PROCESSING COMPOSITIONS CONTAINING MICROPARTICLES | BAXTER INT (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9364443-B2 | Compositions and methods for drug delivery | BAXTER INTERNATIONAL, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2334393-B1 | METHODS OF PROCESSING MULTI-PHASIC DISPERSIONS | BAXTER INT (US) | 2015-12-02 | — | — | EP | disclosed |
| US-6264922-B1 | Nebulized aerosols containing nanoparticle dispersions | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2001-07-24 | — | — | US | disclosed |
| US-5834025-A | REDUCING THE SIDE EFFECT OF ADMINISTERING THE DRUG IN A SUSPENSIONS HAVING A SURFACTANT ADSORBED ON THE DRUG SURFACE | NANOSYSTEMS L.L.C. (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0810853-A4 | AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS | NANOSYSTEMS LLC (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0859604-A1 | REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS | NanoSystems L.L.C. (US) | 1998-08-26 | — | — | EP | disclosed |
| EP-0810853-A1 | AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS | NanoSystems L.L.C. (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997011686-A1 | REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS | NANOSYSTEMS L.L.C. (US) | 1997-04-03 | — | — | WO | disclosed |
| US-5587143-A | ADSORBED ON SURFACE | NANOSYSTEMS L.L.C. (US) | 1996-12-24 | — | — | US | disclosed |
| US-5569448-A | FOR PARTICLES CONTAINING THERAPEUTIC OR DIAGNOSTIC AGENTS; AUTOCLAVE STABILITY | NANO SYSTEMS L.L.C. (US) | 1996-10-29 | — | — | US | disclosed |
| US-5565188-A | Polyalkylene block copolymers as surface modifiers for nanoparticles | NANOSYSTEMS L.L.C. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996025918-A1 | AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS | NANOSYSTEMS L.L.C. (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | SGMS1, CETP, APOB | LMNA 615/4885SMN1; SMN2 1151/4885ALDH1A1 1989/4885 |
| US-10952965-B2 | Compositions and methods for drug delivery | SGMS1, CETP, APOB | LMNA 615/4885SMN1; SMN2 1151/4885ALDH1A1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.